Tag: social

TORONTO, July 25, 2025 (GLOBE NEWSWIRE) -- Purpose Investments Inc. (“Purpose Investments”) announced today its decision to terminate StoneCastle Equity Growth Fund and StoneCastle Income Growth Fund (each, a “StoneCastle Fund” and together, the “StoneCastle Funds”) at the close of business on or about September 29, 2025 (the “StoneCastle Funds’ Termination Date”). Effective immediately, each StoneCastle Fund is closed to new purchases. Purpose Investments also announced its decision to terminate PK Core Fund effective as of the close of business today. PK Core Fund currently has no unitholders and is closed to new purchases.

TORONTO, 25 juill. 2025 (GLOBE NEWSWIRE) -- Investissements Purpose Inc. (« Investissements Purpose ») a annoncé aujourd’hui sa décision de dissoudre le Fonds de croissance des actions StoneCastle et le Fonds de croissance du revenu StoneCastle (chacun, un « Fonds StoneCastle » et, ensemble, les « Fonds StoneCastle ») à la fermeture des bureaux le 29 septembre 2025 ou vers cette date (la « date de dissolution des Fonds StoneCastle »). Dès maintenant, chaque Fonds StoneCastle est fermé aux nouvelles souscriptions. Investissements Purpose a également annoncé sa décision de dissoudre le Fonds de base PK à compter de la fermeture des bureaux aujourd’hui. Le Fonds de base PK n’a actuellement aucun porteur de parts et est fermé aux nouveaux achats.

SOUTH SAN FRANCISCO, July 25, 2025 (GLOBE NEWSWIRE) -- Recognify Life Sciences, a clinical-stage biotech company focused on developing treatments for cognitive impairment, today announced that its randomized, double-blind, placebo-controlled Phase 2b clinical trial evaluating inidascamine (formerly RL-007) in patients with cognitive impairment associated with schizophrenia (CIAS) did not meet its primary endpoint.

Buffalo, NY, July 25, 2025 (GLOBE NEWSWIRE) -- POP Biotechnologies (POP BIO), a biotechnology company specializing in nanoparticle-based vaccines, and the Coalition for Epidemic Preparedness Innovations (CEPI) have announced a new collaboration to accelerate the development of vaccines against future pandemic threats, including a potential ‘Disease X’. Backed by up to $1.5 million in funding from CEPI, the partnership will advance POP BIO’s SNAP™ (Spontaneous Nanoliposome Antigen Particleization) platform—a plug-and-play technology designed to enable rapid-response vaccine development through streamlined protein purification and nanoparticle delivery.

Descriptif du programme de rachat d’actions autorisé par l’Assemblée Générale Mixte du 23 mai 2025 

COURTOIS S.A.

COPENHAGEN, Denmark, July 25, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will be presenting two-year clinical efficacy data from its phase 2 trial with lead compound EVX-01 at the European Society for Medical Oncology (ESMO) Congress 2025 to be held in Berlin, Germany, from October 17-21, 2025.

Major Offshore Acreage Expansion Creates New Growth Platform in the Gulf of Thailand